monte rosa therapeutics inc - GLUE
GLUE
Close Chg Chg %
17.36 -0.99 -5.70%
Closed Market
16.37
-0.99 (5.70%)
Volume: 949.88K
Last Updated:
Jun 5, 2026, 4:00 PM EDT
Company Overview: monte rosa therapeutics inc - GLUE
GLUE Key Data
| Open $17.46 | Day Range 16.25 - 17.80 |
| 52 Week Range 4.12 - 25.77 | Market Cap $1.47B |
| Shares Outstanding 84.48M | Public Float 58.80M |
| Beta 1.60 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.63 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 829.19K |
GLUE Performance
| 1 Week | -16.95% | ||
| 1 Month | -15.58% | ||
| 3 Months | -8.03% | ||
| 1 Year | 226.75% | ||
| 5 Years | N/A |
GLUE Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About monte rosa therapeutics inc - GLUE
Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.
GLUE At a Glance
Monte Rosa Therapeutics, Inc.
321 Harrison Avenue
Boston, Massachusetts 02118
| Phone | 1-617-949-2643 | Revenue | 123.67M | |
| Industry | Biotechnology | Net Income | -38,626,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 63.54% | |
| Fiscal Year-end | 12 / 2026 | Employees | 150 | |
| View SEC Filings |
GLUE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 10.532 |
| Price to Book Ratio | 4.41 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -21.038 |
| Enterprise Value to Sales | 7.80 |
| Total Debt to Enterprise Value | 0.041 |
GLUE Efficiency
| Revenue/Employee | 824,480.00 |
| Income Per Employee | -257,506.667 |
| Receivables Turnover | 10.661 |
| Total Asset Turnover | 0.279 |
GLUE Liquidity
| Current Ratio | 6.123 |
| Quick Ratio | 6.123 |
| Cash Ratio | 5.873 |
GLUE Profitability
| Gross Margin | 93.243 |
| Operating Margin | -43.832 |
| Pretax Margin | -32.12 |
| Net Margin | -31.233 |
| Return on Assets | -8.706 |
| Return on Equity | -16.942 |
| Return on Total Capital | -14.188 |
| Return on Invested Capital | -14.582 |
GLUE Capital Structure
| Total Debt to Total Equity | 16.816 |
| Total Debt to Total Capital | 14.395 |
| Total Debt to Total Assets | 8.735 |
| Long-Term Debt to Equity | 14.929 |
| Long-Term Debt to Total Capital | 12.78 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Monte Rosa Therapeutics Inc - GLUE
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | 75.62M | 123.67M | - |
Sales Growth
| - | - | - | +63.54% | - |
Cost of Goods Sold (COGS) incl D&A
| 8.56M | 6.22M | 8.12M | 8.36M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 8.56M | 6.22M | 8.12M | 8.36M | |
Depreciation
| 8.56M | 6.22M | 8.12M | 8.36M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +301.45% | -27.30% | +30.52% | +2.89% | |
Gross Income
| (8.56M) | (6.22M) | 67.50M | 115.32M | |
Gross Income Growth
| -301.45% | +27.30% | +1,184.88% | +70.84% | |
Gross Profit Margin
| - | - | +89.26% | +93.24% | - |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 103.83M | 137.09M | 148.61M | 169.52M | |
Research & Development
| 76.50M | 105.05M | 113.44M | 133.14M | |
Other SG&A
| 27.32M | 32.04M | 35.17M | 36.38M | |
SGA Growth
| +46.75% | +32.04% | +8.41% | +14.07% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (112.38M) | (143.31M) | (81.11M) | (54.21M) | |
Non Operating Income/Expense
| 3.88M | 8.30M | 10.98M | 14.48M | |
Non-Operating Interest Income
| 3.76M | 9.33M | 10.57M | 12.94M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (108.50M) | (135.01M) | (70.13M) | (39.72M) | |
Pretax Income Growth
| -46.71% | -24.44% | +48.06% | +43.36% | |
Pretax Margin
| - | - | -92.74% | -32.12% | - |
Income Tax
| - | 338.00K | 2.57M | (1.10M) | |
Income Tax - Current - Domestic
| - | - | - | (1.10M) | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (108.50M) | (135.35M) | (72.70M) | (38.63M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (108.50M) | (135.35M) | (72.70M) | (38.63M) | |
Net Income Growth
| -46.71% | -24.75% | +46.29% | +46.87% | |
Net Margin Growth
| - | - | -96.14% | -31.23% | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (108.50M) | (135.35M) | (72.70M) | (38.63M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (108.50M) | (135.35M) | (72.70M) | (38.63M) | |
EPS (Basic)
| -2.2974 | -2.6335 | -0.9836 | -0.465 | |
EPS (Basic) Growth
| -44.55% | -14.63% | +62.65% | +52.72% | |
Basic Shares Outstanding
| 47.23M | 51.40M | 73.91M | 83.07M | |
EPS (Diluted)
| -2.2974 | -2.6335 | -0.9836 | -0.465 | |
EPS (Diluted) Growth
| -44.55% | -14.63% | +62.65% | +52.72% | |
Diluted Shares Outstanding
| 47.23M | 51.40M | 73.91M | 83.07M | |
EBITDA
| (103.83M) | (137.09M) | (72.99M) | (45.85M) | |
EBITDA Growth
| -46.75% | -32.04% | +46.76% | +37.18% | |
EBITDA Margin
| - | - | -96.52% | -37.08% | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 32.333 | |
| Number of Ratings | 8 | Current Quarters Estimate | -0.381 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | -1.656 | |
| Last Quarter’s Earnings | -0.45 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.465 | Next Fiscal Year Estimate | -1.836 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 7 | 7 | 7 | 7 |
| Mean Estimate | -0.38 | -0.40 | -1.66 | -1.84 |
| High Estimates | 0.04 | 0.11 | -0.24 | 0.36 |
| Low Estimate | -0.53 | -0.60 | -2.24 | -2.91 |
| Coefficient of Variance | -51.53 | -59.72 | -39.92 | -57.17 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 8 | 8 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Monte Rosa Therapeutics Inc - GLUE
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Monte Rosa Therapeutics Inc - GLUE
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| May 27, 2026 | Jennifer Champoux Chief Operating Officer | 64,547 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $3.98 per share | 256,897.06 |
| May 27, 2026 | Jennifer Champoux Chief Operating Officer | 62,371 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $19 per share | 1,185,049.00 |
| May 27, 2026 | Jennifer Champoux Chief Operating Officer | 37,824 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 6, 2026 | Markus Warmuth President & CEO; Director | 600,004 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $18.92 per share | 11,352,075.68 |
| Apr 13, 2026 | Philip Nickson Chief Business & Legal Officer | 55,000 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.69 per share | 972,950.00 |
| Apr 8, 2026 | Matthew Bowen Principal Accounting Officer | 25,904 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 8, 2026 | Matthew Bowen Principal Accounting Officer | 19,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 12, 2026 | Markus Warmuth President & CEO; Director | 619,246 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.88 per share | 14,787,594.48 |
| Jan 12, 2026 | Markus Warmuth President & CEO; Director | 618,937 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.57 per share | 15,207,282.09 |